Michael Yee
Stock Analyst at UBS
(3.60)
# 614
Out of 5,180 analysts
111
Total ratings
38.98%
Success rate
10.18%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KOD Kodiak Sciences | Maintains: Buy | $50 → $80 | $38.12 | +109.86% | 5 | Mar 27, 2026 | |
| SDGR Schrödinger | Maintains: Neutral | $18 → $13 | $11.36 | +14.44% | 4 | Mar 17, 2026 | |
| ANAB AnaptysBio | Maintains: Buy | $70 → $90 | $55.46 | +62.28% | 2 | Mar 17, 2026 | |
| NUVB Nuvation Bio | Maintains: Neutral | $10 → $7 | $4.29 | +63.17% | 5 | Mar 3, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $100 → $115 | $114.82 | +0.16% | 2 | Feb 24, 2026 | |
| ABBV AbbVie | Maintains: Neutral | $240 → $230 | $217.49 | +5.75% | 2 | Feb 5, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $535 → $545 | $446.54 | +22.05% | 6 | Jan 26, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $145 → $155 | $139.37 | +11.21% | 5 | Jan 26, 2026 | |
| AMGN Amgen | Maintains: Buy | $380 → $390 | $351.85 | +10.84% | 7 | Jan 26, 2026 | |
| IDYA IDEAYA Biosciences | Assumes: Buy | $50 | $33.32 | +50.06% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $25 | $19.20 | +30.21% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $24 → $55 | $30.15 | +82.42% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $3 → $12 | $5.55 | +116.22% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $19.56 | +155.62% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $49.16 | +22.05% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.83 | +82.77% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $49.05 | +1.94% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $14.91 | +201.81% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $29.85 | +101.01% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $23.83 | +17.50% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.44 | +227.87% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $18.81 | +86.07% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.43 | +169.18% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $46 → $65 | $60.65 | +7.17% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $130 → $185 | $183.33 | +0.91% | 6 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $25 | $28.08 | -10.97% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $1,080 → $1,250 | $919.77 | +35.90% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $3 | $2.01 | +49.63% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $55 | $50.80 | +8.27% | 8 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $424.69 | -9.35% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $5.27 | -43.07% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $14.46 | +38.31% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $2.74 | +994.89% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $9.72 | +208.64% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $27.77 | +332.12% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $67.23 | -55.38% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $17.98 | +328.25% | 2 | Nov 8, 2018 |
Kodiak Sciences
Mar 27, 2026
Maintains: Buy
Price Target: $50 → $80
Current: $38.12
Upside: +109.86%
Schrödinger
Mar 17, 2026
Maintains: Neutral
Price Target: $18 → $13
Current: $11.36
Upside: +14.44%
AnaptysBio
Mar 17, 2026
Maintains: Buy
Price Target: $70 → $90
Current: $55.46
Upside: +62.28%
Nuvation Bio
Mar 3, 2026
Maintains: Neutral
Price Target: $10 → $7
Current: $4.29
Upside: +63.17%
Arcellx
Feb 24, 2026
Downgrades: Neutral
Price Target: $100 → $115
Current: $114.82
Upside: +0.16%
AbbVie
Feb 5, 2026
Maintains: Neutral
Price Target: $240 → $230
Current: $217.49
Upside: +5.75%
Vertex Pharmaceuticals
Jan 26, 2026
Maintains: Buy
Price Target: $535 → $545
Current: $446.54
Upside: +22.05%
Gilead Sciences
Jan 26, 2026
Maintains: Buy
Price Target: $145 → $155
Current: $139.37
Upside: +11.21%
Amgen
Jan 26, 2026
Maintains: Buy
Price Target: $380 → $390
Current: $351.85
Upside: +10.84%
IDEAYA Biosciences
Jan 7, 2026
Assumes: Buy
Price Target: $50
Current: $33.32
Upside: +50.06%
Jan 7, 2026
Assumes: Buy
Price Target: $25
Current: $19.20
Upside: +30.21%
Jan 7, 2026
Assumes: Buy
Price Target: $24 → $55
Current: $30.15
Upside: +82.42%
Jan 7, 2026
Assumes: Buy
Price Target: $3 → $12
Current: $5.55
Upside: +116.22%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $19.56
Upside: +155.62%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $49.16
Upside: +22.05%
Jan 7, 2026
Initiates: Buy
Price Target: $7
Current: $3.83
Upside: +82.77%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $49.05
Upside: +1.94%
Jan 7, 2026
Initiates: Buy
Price Target: $45
Current: $14.91
Upside: +201.81%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $29.85
Upside: +101.01%
Jan 7, 2026
Initiates: Neutral
Price Target: $28
Current: $23.83
Upside: +17.50%
Jan 7, 2026
Initiates: Buy
Price Target: $8
Current: $2.44
Upside: +227.87%
Jan 7, 2026
Initiates: Buy
Price Target: $35
Current: $18.81
Upside: +86.07%
Jan 7, 2026
Initiates: Buy
Price Target: $20
Current: $7.43
Upside: +169.18%
Jan 7, 2026
Upgrades: Buy
Price Target: $46 → $65
Current: $60.65
Upside: +7.17%
Jan 7, 2026
Assumes: Neutral
Price Target: $130 → $185
Current: $183.33
Upside: +0.91%
Jan 7, 2026
Assumes: Neutral
Price Target: $25
Current: $28.08
Upside: -10.97%
Jan 7, 2026
Assumes: Buy
Price Target: $1,080 → $1,250
Current: $919.77
Upside: +35.90%
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $2.01
Upside: +49.63%
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $50.80
Upside: +8.27%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $424.69
Upside: -9.35%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $5.27
Upside: -43.07%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $14.46
Upside: +38.31%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $2.74
Upside: +994.89%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $9.72
Upside: +208.64%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $27.77
Upside: +332.12%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $67.23
Upside: -55.38%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $17.98
Upside: +328.25%